Hans Konrad Müller‐Hermelink

Author

Also Known As

H K Muller-Hermelink, H K MÜLLER-HERMELINK, H K Müller-Hermelink, H K Műller-Hermelink, H Konrad Müller-Hermelink, H MullerHermelink, H. K. Muller-Hermelink, H. K. MÜller-Hermelink, H. K. Müller-Hermelink, H. K. Müller‐Hermelink

258

Publications

26.7K

Citations

H-Index

141

Concepts

All Affiliations

University of Würzburg National Cancer Institute Universitätsklinikum Würzburg University of Nebraska Medical Center Universitat de Barcelona

About

Hans Konrad Müller‐Hermelink is an author at University of Würzburg specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	74	13.3K
2	Health Sciences	4	4	836
3	Engineering	2	2	80
4	Education	1	1	11
5	Natural Sciences	1	1	276

Hans Konrad Müller‐Hermelink

157

Publications

25.3K

Citations

H-Index

Page 1

	Year	Citations
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997 Nancy L. Harris, Elaine S. Jaffe, J Diébold, Journal of Clinical Oncology	1999	3.3K
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma R. Eric Davis, Vu N. Ngo, Georg Lenz, Nature Lymphoid NeoplasiaImmunologyPathologyAdult T-cell Leukemia-lymphomaMedicine	2010	1.6K
Oncogenically active MYD88 mutations in human lymphoma Vu N. Ngo, Ryan M. Young, Roland Schmitz, Nature Tumor BiologyLymphoid NeoplasiaPathologyActive Myd88 MutationsMedicine	2010	1.5K
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma Andreas Rosenwald, George W. Wright, Karen Leroy, The Journal of Experimental Medicine Molecular DiagnosisImmunologyPathologyImmunotherapyHematological Malignancy	2003	1.1K
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Georg Lenz, George W. Wright, N. C. Tolga Emre, Proceedings of the National Academy of Sciences	2008	973
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics Roland Schmitz, Ryan M. Young, Michele Ceribelli, Nature Lymphoid NeoplasiaFunctional GenomicsImmunologyTherapeutic TargetsLymphatic System	2012	908
Oncogenic <i>CARD11</i> Mutations in Human Diffuse Large B Cell Lymphoma Georg Lenz, R. Eric Davis, Vu N. Ngo, Science Hematological MalignancyTumor BiologyLymphoid NeoplasiaOncologyMedicine	2008	869
The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues Nancy L. Harris, Elaine S. Jaffe, J Diébold, Annals of Oncology Hematological MalignancyNeoplastic DiseasesLymphoid NeoplasiaTumoral PathologyLymphoid Tissues	1999	844
Admission criteria for immunogerontological studies in man: The senieur protocol Gerard J. Ligthart, J Corberand, Catherine Fournier, Mechanisms of Ageing and Development Primary ImmunodeficiencyHistocompatibilityAllergyAutoimmune DiseaseMedicine	1984	754
Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group Andreas Engert, Petra Schiller, Andreas Josting, Journal of Clinical Oncology	2003	456

Page 1